Sun Pharma’s Ilumya Hits Key Milestone—What It Means for Millions with Joint Disease

Sun Pharma's Ilumya (tildrakizumab-asmn) posted promising Phase 2b trial results that will pave the way for a possible US filing for the treatment of psoriatic arthritis. The medicine, already approved for plaque psoriasis, demonstrated robust efficacy in alleviating joint symptoms.

 

Key clinical milestones:

 

- 71.4% to 79.5% of the patients were ACR20 responders at Week 24, compared with 50.6% on placebo.

 

- Both 100 mg and 200 mg quarterly regimens were similarly improved.

 

- A few patients had relief from symptoms as early as Week 8.

 

- Ilumya met its primary endpoint with low rates of serious adverse events (3.3%), comparable to placebo.

 

Safety and tolerability:

 

- The most frequent side effects were nasopharyngitis, upper respiratory infections, and headache.

 

- No inflammatory bowel, malignancy, or any major cardiac event had occurred.

 

These results are a complement to Sun Pharma's strategic initiative to expand Ilumya's indications and establish its specialty portfolio.

 

Sources: Drugs.com, American Pharmaceutical Review, Sun Pharma Press Release.